These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 5086635)

  • 21. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
    Constantinidis J; de Ajuriaguerra J
    Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
    [No Abstract]   [Full Text] [Related]  

  • 22. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 26. Experimental evaluation of L-dopa penetration in brain.
    De la Torre JC; Mullan S
    Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088
    [No Abstract]   [Full Text] [Related]  

  • 27. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
    Fischer PA
    Nervenarzt; 1974 Dec; 45(12):617-27. PubMed ID: 4614096
    [No Abstract]   [Full Text] [Related]  

  • 29. [Medical treatment of Parkinson's disease].
    Castaigne P; Rondot P; Ribadeau-Dumas JL
    Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040
    [No Abstract]   [Full Text] [Related]  

  • 30. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC; Schwieger AC
    Med J Aust; 1971 Oct; 2(14):693-700. PubMed ID: 5114186
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 33. [A new determination method of L-dopa in blood (author's transl)].
    Weitbrecht WU; Birg W; Metzel E; Mundinger F
    Med Klin; 1974 Mar; 69(12):500-1. PubMed ID: 4831452
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 36. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 37. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE; Dahl LK; Cotzias GC
    Trans Assoc Am Physicians; 1971; 84():289-96. PubMed ID: 5164305
    [No Abstract]   [Full Text] [Related]  

  • 38. Augmenting the action of levodopa.
    Rao SK; Vakil SD; Calne DB; Hilson A
    Postgrad Med J; 1972 Nov; 48(565):653-6. PubMed ID: 4568331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 40. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.